The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple myeloma after treatment.

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

The study evaluated the efficacy and safety of the investigational immunotherapy combination of TECVAYLI ® plus DARZALEX FASPRO ® versus DARZALEX FASPRO ® and dexamethasone with either pomalidomide or ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months -- -- No delayed ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...

The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has changed dramatically over the past decade, resulting in more therapeutic options for various stages of relapse. In a ...